Gene Therapy Partnering Terms and Agreements

Published: July 2013
No. of Pages: 239
  

The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in gene therapypartnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Gene therapypartnering contract documents
  • Top gene therapy deals by value

The Gene Therapy Partnering Terms and Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter gene therapypartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2007 including financial terms where available including over 300 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in gene therapy dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading gene therapy deals since 2007. Deals are listed by headline value, signed by bigpharma and big biotechcompanies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of gene therapy deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followed by a comprehensive listing of gene therapy deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of gene therapy partnering deals signed and announced since 2007. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and specific therapy focus

Chapter 7 provides a comprehensive and detailed review of technology specific (gene therapy and oligonucleotide) partnering deals signed and announced since 2007. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand

The report also includes numerous tables and figures that illustrate the trends and activities in gene therapy partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of gene therapy technologies and products.

Key Benefits

Gene Therapy Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of gene therapy deal trends since 2007
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of gene therapy agreements with numerous real life case studies
  • Comprehensive access to over 100 actual gene therapy contracts entered into by the world’s biopharma companies
  • Detailed access to actual gene therapy contracts enter into by the leading fifty bigpharma
  • Insight into the terms included in gene therapy agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Gene Therapy Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to gene therapy trends and structure of deals entered into by leading companies worldwide.

Gene Therapy Partnering Terms and Agreements includes:

  • Trends in gene therapy dealmaking in the biopharma industry since 2007
  • Analysis of gene therapy deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life gene therapy deals
  • Access to over 300 gene therapy contract documents
  • The leading antibody deals by value since 2007
  • Most active gene therapy dealmakers since 2007
  • The leading gene therapy partnering resources

In Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Gene Therapy Partnering Terms and Agreements

Table Of Contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in gene therapy dealmaking
2.1. Introduction
2.2. Gene therapy partnering over the years
2.3. Bigpharma gene therapy dealmaking activity
2.5. Most active in gene therapy partnering
2.6. Gene therapy partnering by deal type
2.7. Gene therapy partnering by disease type
2.8. Partnering by gene therapy technology type
2.9. Average deal terms for gene therapy partnering
2.9.1 Gene therapy headline values
2.9.2 Gene therapy upfront payments
2.9.3 Gene therapy milestone payments
2.9.4 Gene therapy royalty rates
2.10. The anatomy of gene therapy partnering
2.10. The anatomy of a gene therapy deal
2.10.a. Case study 1: Novartis, Quark Pharmaceuticals-2010
2.10.b. Case study 2: OncoGenex Pharmaceuticals, Teva Pharmaceuticals: Dec 2009

Chapter 3 – Leading gene therapy deals
3.1. Introduction
3.2. Top gene therapy deals by value
3.3. Top big pharma gene therapy deals by value

Chapter 4 – Bigpharma gene therapy deals
4.1. Introduction
4.2. How to use bigpharma gene therapy partnering deals
4.3. Big pharma gene therapy partnering company profiles
Amgen
Baxter International
Celgene
Daiichi Sankyo
GlaxoSmithKline
Merck & Co
Mitsubishi Tanabe
Novartis
Pfizer
Roche
Sanofi
Servier
Takeda
Teva

Chapter 5  – Gene therapy partnering contracts directory
5.1. Introduction
5.2. Company A-Z
5.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Option
Research
Supply
Technology transfer
Termination
5.4. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
5.5. By therapy area
Cardiovascular
Central Nervous System
Genetic disorders
Genitourinary
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Pediatrics
Respiratory

Chapter 6 – Gene therapy dealmaking by technology type
6.1. Introduction
6.2. Deals by gene therapy technology type

Appendices
Appendix 1 – Gene therapy partnering resource center
Online gene therapy partnering
Gene therapy partnering events
Further reading on antibody dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

List Of Figures

Figure 1: Gene therapy partnering since 2007
Figure 2: Bigpharma – top 50 – gene therapy deals 2007 to 2013
Figure 3: Bigpharma gene therapy deal frequency – 2007 to 2013
Figure 4: Active gene therapy dealmaking activity– 2007 to 2013
Figure 5: Gene therapy partnering by deal type since 2007
Figure 6: Gene therapy partnering by disease type since 2007
Figure 7: Gene therapy partnering by technology type since 2007
Figure 8: Gene therapy deals with a headline value
Figure 9: Gene therapy deal headline value distribution, US$million – discovery stage
Figure 10: Gene therapy deal headline value distribution, US$million – preclinical stage
Figure 11: Gene therapy deal headline value distribution, US$million – phase I stage
Figure 12: Gene therapy deal headline value distribution, US$million – phase II stage
Figure 13: Gene therapy deal headline value distribution, US$million – phase III stage
Figure 14: Gene therapy deal headline value distribution, US$million – regulatory stage
Figure 15: Gene therapy deal headline value distribution, US$million – marketed stage
Figure 16: Summary median headline value by stage of development, 2007-2013
Figure 17: Gene therapy deals with upfront payment values
Figure 18: Gene therapy deal upfront payment distribution, US$million – discovery stage
Figure 19: Gene therapy deal upfront payment distribution, US$million – preclinical stage
Figure 20: Gene therapy deal upfront payment distribution, US$million – phase I stage
Figure 21: Gene therapy deal upfront payment distribution, US$million – phase II stage
Figure 22: Gene therapy deal upfront payment distribution, US$million – phase III stage
Figure 23: Gene therapy deal upfront payment distribution, US$million – regulatory stage
Figure 24: Gene therapy deal upfront payment distribution, US$million – marketed stage
Figure 25: Summary median upfront payments by stage of development, 2007-2013
Figure 26: Gene therapy deals with milestone payments
Figure 27: Gene therapy deal milestone distribution, US$million – discovery stage
Figure 28: Gene therapy deal milestone distribution, US$million – preclinical stage
Figure 29: Gene therapy deal milestone distribution, US$million – phase I stage
Figure 30: Gene therapy deal milestone distribution, US$million – phase II stage
Figure 31: Gene therapy deal milestone distribution, US$million – phase III stage
Figure 32: Gene therapy deal milestone distribution, US$million – regulatory stage
Figure 33: Gene therapy deal milestone distribution, US$million – marketed stage
Figure 34: Gene therapy deals with royalty rates, %
Figure 35: Gene therapy deal royalty rate distribution, US$million – discovery stage
Figure 36: Gene therapy deal royalty rate distribution, US$million – preclinical stage
Figure 37: Gene therapy deal royalty rate distribution, US$million – phase I stage
Figure 38: Gene therapy deal royalty rate distribution, US$million – phase II stage
Figure 39: Gene therapy deal royalty rate distribution, US$million – phase III stage
Figure 40: Gene therapy deal royalty rate distribution, US$million – regulatory stage
Figure 41: Gene therapy deal royalty rate distribution, US$million – marketed stage
Figure 42: Summary median royalty rate by stage of development, 2007-2013
Figure 43: Components of the typical gene therapy deal structure
Figure 44: Top gene therapy deals by value since 2007
Figure 45: Top gene therapy deals by value since 2007
Figure 46: Online partnering resources
Figure 47: Forthcoming partnering events

Published By: Current Partnering
Product Code: Current Partnering37


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:

  • Diagnostics Partnering Terms and Agreements

    The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.The report provides a detai...

  • Vaccine Partnering Terms and Agreements

    The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in vaccine a...

  • Drug Delivery Partnering Terms and Agreements

    The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.The report p...

  • Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

    The Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma compani...

  • Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

    The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by th...

  • Cancer Vaccine Partnering Terms and Agreements

    The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.Trends in cancer vaccine partnerin...

  • Cancer Diagnostics Partnering Terms and Agreements

    The Cancer Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.Th...

  • Monoclonal Antibodies Partnering Terms and Agreements

    The Monoclonal Antibodies Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the monoclonal antibodies partnering deals and agreements entered into by the worlds leading healthcare compani...

  • Infectives Vaccine Partnering Terms and Agreements

    The Infectives vaccine partnering terms and agreements report provides a detailed understanding and analysis of how and why companies enter infectives vaccine partnering deals. The majority of deals are development stage whereby the licensee obtai...

  • Discovery Stage Partnering Terms and Agreements

    The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare com...


Why ReportsnReports.com?

  • 400,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100